Precision BioSciences Inc. (DTIL) - Multiplikator Forward P/S
Patent protection for ARCUS software creates a long-term foundation for license monetization for Precision BioSciences (DTIL). The expected P/S ratio clearly demonstrates the business valuation dynamics, where 4.90 represents the current metric level. Precision BioSciences is actively developing hepatitis B therapies, while high barriers to entry in bioengineering and a shortage of skilled personnel effectively limit competition within the segment.
Rincian analitis perusahaan Precision BioSciences
- rega saham lan target rega konsensus:
- indikator kapitalisasi pasar:
- statistik nilai buku emiten:
- rincian struktur utang lan likuiditas bisnis:
Utang marang Ekuitas Precision BioSciences|DTIL - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang modal Precision BioSciences, Inc.|DTIL - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Precision BioSciences, Inc.|DTIL - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Precision BioSciences|Likuiditas cepet precisionbiosciences.com
- rincian asil keuangan lan kelipatan valuasi:
DTIL - Bathi perusahaan|Proyeksi bathi mangsa ngarep Precision BioSciences|DTIL - Koefisien rega marang bathi|Pangali Forward P/E Precision BioSciences|DTIL - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Precision BioSciences, Inc.|DTIL - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Precision BioSciences|DTIL - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan precisionbiosciences.com|DTIL - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Precision BioSciences
- indikator volume dodolan lan pendapatan:
Analisis kabeh metrik perusahaan:Precision BioSciences DTIL
The forward P/S reflects the ratio of market capitalization to expected sales volume, allowing for an assessment of whether an asset is overvalued or undervalued relative to future cash flows. Amid geopolitical risks for Precision BioSciences (DTIL) affecting global research and patents, the projected P/S metric helps distinguish a fundamental discount from a systemic devaluation of the business caused by operational barriers.
Analisis perusahaan pesaing
Tempus AI, Inc. - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan QGEN|Ionis Pharma - Multiplikator Forward P/S|RGEN: Rasio rega marang prakiraan pendapatan|RNA: Multiplikator Forward P/S|CRSP - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan GeneDx|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Ultragenyx Pharmaceutical Inc. RARE|Rasio rega marang prakiraan pendapatan Beam Therapeutics Corp (BEAM)|Rasio kapitalisasi marang dodolan sing dikarepake Sarepta Corp|Multiplikator Forward P/S TWST (Twist Bioscience)|TXG - Multiplikator forward rega marang pendapatan|Intellia Therapeutics, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Stoke Therapeutics Inc STOK|BLFS: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Wave Pharma (WVE)|Rasio rega marang prakiraan pendapatan Maze Therapeutics Inc|Kapitalisasi marang prakiraan pendapatan SION (sionnatx.com)|Multiplikator Forward P/S PRME|Multiplikator forward rega marang pendapatan Taysha Gene Therapies Inc TSHA|Multiplikator Forward P/S QURE (uniQure Corp)|MeiraGTx Corp (MGTX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|RGNX - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake solidbio.com SLDB|OCGN: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan PACB|Multiplikator forward rega marang pendapatan BNTC|DSGN (Design Corp) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S RCKT|Rasio kapitalisasi marang dodolan sing dikarepake 4dmoleculartherapeutics.com|Rasio rega marang prakiraan pendapatan Lexeo Therapeutics, Inc. LXEO|Korro Bio Inc. - Rasio rega marang prakiraan pendapatan|Editas - Multiplikator Forward P/S|SLN (Silence Therapeutics Corp) - Kapitalisasi marang prakiraan pendapatan|proqr.com (PRQR) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan CDXS|SGMO (Sangamo Therapeutics, Inc.) - Multiplikator Forward P/S|Multiplikator Forward P/S Nautilus Biotechnology Inc|Rasio rega marang prakiraan pendapatan Metagenomi, Inc (MGX)|GBIO: Rega mangsa ngarep marang pendapatan|Rasio rega marang prakiraan pendapatan Boundless Bio, Inc. BOLD|Rega forward marang dodolan XCUR|Celsion Corporation - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Phio Pharmaceuticals|MBIO: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan TransCode Therapeutics, Inc.|BNGO (Bionano Genomics Inc.) - Multiplikator Forward P/S|adnas.com (APDN) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan bluebird bio (BLUE)|Rasio kapitalisasi marang dodolan sing dikarepake immunoprecise.com|Multiplikator Forward P/S OMGA (Omega)|Rasio kapitalisasi marang dodolan sing dikarepake Singular Genomics Corp (OMIC)|RGLS - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep syros.com|Telesis Bio (TBIO) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan TCON|Multiplikator forward rega marang pendapatan UBX
